Indoco has carved a place for itself in the international arena and is exporting a number of generic products
in the Regulated and Emerging Markets. Our products are distributed in over 55 countries across the globe.
Our branded formulations are promoted in Emerging Markets of South East Asia, Africa, Latin America and CIS
countries. We have tie-ups with big generic companies and work in close coordination with customers for
leveraging our core competencies.
The company has 9 manufacturing facilities, out of which 6 are for finished dosages and 3 for APIs, supported by a
state-of-the-art R&D centre at Rabale, Navi Mumbai and a CRO at Hyderabad. The facilities have been approved by
various regulatory authorities such as USFDA, UK-MHRA, SUKL-Czech Republic, Cofepris-Mexico, TGA-Australia,
JAZMP-Slovenia, MCC-South Africa, NDA-Uganda, TFDA-Tanzania, SBD-Yemen, MOH-Ukraine, PPB-Kenya and FDB-Ghana.
The Company's strategy to focus on niche segments of Ophthalmics and Injectables for US market, filing of dossiers
in Own name in EU and brand building in Emerging markets, will help the Company to achieve a sustainable growth.
International business will continue to remain a thrust area and is slated to contribute to more than 50% of Indoco's
total revenues in future.